Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ 3 by Cdk5

Nature

Volumn 466, Issue 7305, 2010, Pages 451-456

  Choi, Jang Hyun ^a   Banks, Alexander S ^a   Estall, Jennifer L ^a   Kajimura, Shingo ^a   Boström, Pontus ^a   Laznik, Dina ^a   Ruas, Jorge L ^a   Chalmers, Michael J ^b   Kamenecka, Theodore M ^b   Blüher, Matthias ^c   Griffin, Patrick R ^b   Spiegelman, Bruce M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; ANTIDIABETIC AGENT; CYCLIN DEPENDENT KINASE 5; GLITAZONE DERIVATIVE; INSULIN; INSULIN SENSITIZING AGENT; MRL 24; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RECEPTOR; ROSCOVITINE; ROSIGLITAZONE; UNCLASSIFIED DRUG;

DIABETES; DRUG; ENZYME ACTIVITY; FAT; GENE EXPRESSION; LIGAND; OBESITY;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG INHIBITION; DRUG RECEPTOR BINDING; GENE EXPRESSION; HUMAN; HUMAN CELL; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; TRANSCRIPTION REGULATION;

ADIPOSE TISSUE; AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CYCLIN-DEPENDENT KINASE 5; DIABETES MELLITUS, EXPERIMENTAL; DIETARY FATS; HUMANS; INSULIN; LIGANDS; MICE; MODELS, MOLECULAR; OBESITY; PHOSPHORYLATION; PHOSPHOSERINE; PPAR GAMMA; PROTEIN CONFORMATION; THIAZOLIDINEDIONES;

MUS;

EID: 77954941113     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature09291     Document Type: Article

References (46)

1. Kershaw, E. E. & Flier, J. S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89, 2548-2556 (2004).
2. Hotamisligil, G. S., Shargill, N. S. & Spiegelman, B. M. Adipose expression of tumor necrosis factor-a: direct role in obesity-linked insulin resistance. Science 259, 87-91 (1993).
3. Lagathu, C. et al. Long-term treatment with interleukin-1b induces insulin resistance in murine and human adipocytes. Diabetologia 49, 2162-2173 (2006).
4. Steppan, C. M. et al. The hormone resistin links obesity to diabetes. Nature 409, 307-312 (2001).
5. Berg, A. H. et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Med. 7, 947-953 (2001).
6. Hu, E., Liang, P. & Spiegelman, B. M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 271, 10697-10703 (1996).
7. Yamauchi, T. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med. 7, 941-946 (2001).
8. Morrison, R. F. & Farmer, S. R. Hormonal signaling and transcriptional control of adipocyte differentiation. J. Nutr. 130, 3116S-3121S (2000).
9. Tontonoz, P., Hu, E. & Spiegelman, B. M. Stimulation of adipogenesis in fibroblasts by PPAR c 2, a lipid-activated transcription factor. Cell 79, 1147-1156 (1994).
10. Willson, T. M., Lambert, M. H. & Kliewer, S. A. Peroxisome proliferator-activated receptor c and metabolic disease. Annu. Rev. Biochem. 70, 341-367 (2001).
11. Jimenez, M. A. et al. Critical role for Ebf1 and Ebf2 in the adipogenic transcriptional cascade. Mol. Cell. Biol. 27, 743-757 (2007).
12. Wu, Z., Bucher, N. L. & Farmer, S. R. Induction of peroxisome proliferator-activated receptor c during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPb, C/EBPd, and glucocorticoids. Mol. Cell. Biol. 16, 4128-4136 (1996).
13. Lehmann, J. M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor c (PPAR c). J. Biol. Chem. 270, 12953-12956 (1995).
14. Trujillo, M. E. & Scherer, P. E. Adipose tissue-derived factors: impact on health and disease. Endocr. Rev. 27, 762-778 (2006).
15. Sharma, A. M. & Staels, B. Peroxisome proliferator-activated receptor c and adipose tissue\understanding obesity-related changes in regulation of lipid and glucose metabolism. J. Clin. Endocrinol. Metab. 92, 386-395 (2007).
16. Lipscombe, L. L. et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. J. Am. Med. Assoc. 298, 2634-2643 (2007).
17. Willson, T. M. et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 39, 665-668 (1996).
18. Acton, J. J. III et al. Benzoyl 2-methyl indoles as selective PPARc modulators. Bioorg. Med. Chem. Lett. 15, 357-362 (2005).
19. Dhavan, R. & Tsai, L. H. A decade of CDK5. Nature Rev. Mol. Cell Biol. 2, 749-759 (2001).
20. Utreras, E. et al. Tumor necrosis factor-a regulates cyclin-dependent kinase 5 activity during pain signaling through transcriptional activation of p35. J. Biol. Chem. 284, 2275-2284 (2009).
21. Rosen, E. D. et al. C/EBPa induces adipogenesis through PPARc: a unified pathway. Genes Dev. 16, 22-26 (2002).
22. Musa, F. R. et al. Effects of luteinizing hormone, follicle-stimulating hormone, and epidermal growth factor on expression and kinase activity of cyclin-dependent kinase 5 in Leydig TM3 and Sertoli TM4 cell lines. J. Androl. 21, 392-402 (2000).
23. Torti, F. M. et al. A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science 229, 867-869 (1985).
24. Cinti, S. The adipose organ. Prostaglandins Leukot. Essent. Fatty Acids 73, 9-15 (2005).
25. Leesnitzer, L. M. et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41, 6640-6650 (2002).
26. Sarraf, P. et al. Loss-of-function mutations in PPARc associated with human colon cancer. Mol. Cell 3, 799-804 (1999).
27. Berger, J. P. et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein c selective modulator. Mol. Endocrinol. 17, 662-676 (2003).
28. Gregoire, F. M. et al. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol. Endocrinol. 23, 975-988 (2009).
29. Ostberg, T. et al. A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J. Biol. Chem. 279, 41124-41130 (2004).
30. Hakak, Y. et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl Acad. Sci. USA 98, 4746-4751 (2001).
31. Salim, C. et al. The giant protein AHNAK involved in morphogenesis and laminin substrate adhesion of myelinating Schwann cells. Glia 57, 535-549 (2009).
32. Merino-Trigo, A. et al. Sorting nexin 5 is localized to a subdomain of the early endosomes and is recruited to the plasma membrane following EGF stimulation. J. Cell Sci. 117, 6413-6424 (2004).
33. Maier, C. S. & Deinzer, M. L. Protein conformations, interactions, and H/D exchange. Methods Enzymol. 402, 312-360 (2005).
34. Nolte, R. T. et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-c. Nature 395, 137-143 (1998).
35. Bruning, J. B. et al. Partial agonists activate PPARc using a helix 12 independent mechanism. Structure 15, 1258-1271 (2007).
36. Flier, J. S. et al. Severely impaired adipsin expression in genetic and acquired obesity. Science 237, 405-408 (1987).
37. Calle, E. E. et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348, 1625-1638 (2003).
38. Whitmer, R. A. et al. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. Br. Med. J. 330, 1360-1362 (2005).
39. Patrick, G. N. et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402, 615-622 (1999).
40. Kinsella, T. M. & Nolan, G. P. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum. Gene Ther. 7, 1405-1413 (1996).
41. Walkey, C. J. & Spiegelman, B. M. A functional peroxisome proliferator-activated receptor-c ligand-binding domain is not required for adipogenesis. J. Biol. Chem. 283, 24290-24294 (2008).
42. Lockhart, D. J. et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nature Biotechnol. 14, 1675-1680 (1996).
43. Li, C. & Wong, W. H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl Acad. Sci. USA 98, 31-36 (2001).
44. Moreno-Navarrete, J. M. et al. Complement factor H is expressed in adipose tissue in association with insulin resistance. Diabetes 59, 200-209 (2010).
45. Kloting, N. et al. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab. 6, 79-87 (2007).
46. Bluher, M. et al. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes. Diabetologia 45, 210-216 (2002).